Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

The company recently released phase 3 data showing that a twice-yearly treatment with lenacapavir was 100% effective in HIV ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

But Namibia's community-based HIV education and prevention schemes have received ... said stigma is still a major obstacle to life-saving treatment for marginalized people, such as those who ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...